HeXun Biosciences Co., Ltd.

TWO:6986 Taiwan Biotechnology
Market Cap
$76.33 Million
NT$2.53 Billion TWD
Market Cap Rank
#23052 Global
#1351 in Taiwan
Share Price
NT$54.90
Change (1 day)
+6.60%
52-Week Range
NT$51.10 - NT$61.90
All Time High
NT$61.90
About

HeXun Biosciences Co., Ltd. engages in the research and development of stem cell drug development and cardiovascular disease treatments in Taiwan. It provides contract manufacturing; commissioned inspection; aseptic filling; and consulting services. The company was founded in 2019 and is based in Taoyuan City, Taiwan.

HeXun Biosciences Co., Ltd. - Asset Resilience Ratio

Latest as of September 2025: 29.15%

HeXun Biosciences Co., Ltd. (6986) has an Asset Resilience Ratio of 29.15% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets
NT$231.13 Million
Cash + Short-term Investments
Total Assets
NT$792.78 Million
All company assets
Resilience Assessment
Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2022–2024)

This chart shows how HeXun Biosciences Co., Ltd.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.

Liquid Assets Composition Over Time

This chart breaks down HeXun Biosciences Co., Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents NT$0.00 0%
Short-term Investments NT$231.13 Million 29.15%
Total Liquid Assets NT$231.13 Million 29.15%

Asset Resilience Insights

  • Very High Liquidity: HeXun Biosciences Co., Ltd. maintains exceptional liquid asset reserves at 29.15% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

HeXun Biosciences Co., Ltd. Industry Peers by Asset Resilience Ratio

Compare HeXun Biosciences Co., Ltd.'s asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
MedPacto Inc
KQ:235980
Biotechnology 49.82%
Shenzhen CAU Technology Co Ltd
SHE:000004
Biotechnology 6.20%
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
Biotechnology 6.88%
Nanhua Bio Medicine Co Ltd
SHE:000504
Biotechnology 11.93%
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
Biotechnology 0.03%
Chengzhi Shareholding Co Ltd
SHE:000990
Biotechnology 6.73%
Hualan Biological EngineeringInc
SHE:002007
Biotechnology 14.68%
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030
Biotechnology 4.35%

Annual Asset Resilience Ratio for HeXun Biosciences Co., Ltd. (2022–2024)

The table below shows the annual Asset Resilience Ratio data for HeXun Biosciences Co., Ltd..

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 24.33% NT$172.00 Million NT$706.92 Million +11.73pp
2023-12-31 12.60% NT$72.00 Million NT$571.43 Million -5.22pp
2022-12-31 17.82% NT$72.00 Million NT$404.15 Million --
pp = percentage points